Patents Examined by Rachel B Gill
  • Adeno-associated viral vectors for gene therapy
    Patent number: 11098325
    Abstract: Genetically modified compositions, such as adeno-associated viral vectors and primary cells, for treating various conditions and diseases. Disclosed are also modified adeno-associated viruses for the treatment of cancer. Also disclosed are the methods of making and using the genetically modified compositions in treating various diseases, conditions, and cancer.
    Type: Grant
    Filed: December 18, 2019
    Date of Patent: August 24, 2021
    Assignee: INTIMA BIOSCIENCE, INC.
    Inventors: Thomas Henley, Mavis Agbandje-McKenna, Tilmann Buerckstuemmer, Lydia Viney, Modassir Choudhry
  • Scalable purification method for AAV9
    Patent number: 11098286
    Abstract: A two-step chromatography purification scheme is described which selectively captures and isolates the genome-containing rAAV vector particles from the clarified, concentrated supernatant of a rAAV production cell culture. The process utilizes an affinity capture method performed at a high salt concentration followed by an anion exchange resin method performed at high pH to provide rAAV vector particles which are substantially free of rAAV intermediates.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: August 24, 2021
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Martin Lock, Mauricio Alvira
  • Recombinant cytomegalovirus vectors as vaccines for tuberculosis
    Patent number: 11091775
    Abstract: The present disclosure provides cytomegalovirus vectors encoding fusion proteins comprising Mycobacterium tuberculosis (Mtb) antigens, nucleic acid molecules encoding the same, cytomegalovirus vectors comprising nucleic acid molecules, compositions comprising the same, and methods of eliciting an immune response against tuberculosis.
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: August 17, 2021
    Assignees: Oregon Health and Science University, International AIDS Vaccine Initative, Inc.
    Inventors: Thomas G. Evans, Ravi P. Anantha, Aurelio M. Bonavia, Dominick J. Laddy, Louis Picker, Scott Hansen, Guangwu Xu
  • Methods and compositions useful in generating non canonical CD8+ T cell responses
    Patent number: 11091779
    Abstract: Methods of inducing a CD8+ T cell response to a heterologons antigen in which at least 10% of the CD8+ T cells are MHC-E restricted are disclosed. The method involves immunizing with a CMV vector that does not express UL128 and UL130 proteins. Also disclosed are recombinant CMV vectors comprising nucleic acids encoding a heterologous protein antigen, a UL40 protein, and a US28 protein but that do not express an active UL128 and UL130 protein. Also, disclosed are recombinant CMV vectors comprising nucleic acids encoding a heterologous protein antigen, but that do not express an active UL40 protein, UL128 protein, UL130 protein, and optionally a US28 protein. Also disclosed are recombinant CMV vectors comprising nucleic acids encoding a heterologous protein antigen, but that do not express an active US28 protein, UL128 protein, UL130 protein, and optionally a UL40 protein.
    Type: Grant
    Filed: January 9, 2020
    Date of Patent: August 17, 2021
    Assignee: OREGON HEALTH & SCIENCE UNIVERSITY
    Inventors: Klaus Frueh, Louis Picker, Scott Hansen, Jonah Sacha, Daniel Malouli
  • Bacteriophage strains and their applications
    Patent number: 11077155
    Abstract: New strains of bacteriophages and their applications are revealed, useful especially in fish farming.
    Type: Grant
    Filed: April 3, 2017
    Date of Patent: August 3, 2021
    Assignee: PROTEON PHARMACEUTICALS S.A.
    Inventors: Arkadiusz Wojtasik, Elzbieta Gorecka, Ewelina Wojcik, Malgorzata Stanczyk, Joanna Kolsut, Justyna Klimczak, Jaroslaw Dastych, Andrzej Siwicki, Patrycja Schulz
  • Antigen delivery platforms
    Patent number: 11078237
    Abstract: This disclosure provides platforms for delivery of herpes virus proteins to cells, particularly proteins that form complexes in vivo. In some embodiments these proteins and the complexes they form elicit potent neutralizing antibodies. Thus, presentation of herpes virus proteins using the disclosed platforms permits the generation of broad and potent immune responses useful for vaccine development.
    Type: Grant
    Filed: August 28, 2018
    Date of Patent: August 3, 2021
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Michael Franti, Anders Lilja, Rebecca Loomis, Peter W. Mason
  • High titer recombinant AAV vector production in adherent and suspension cells
    Patent number: 11078464
    Abstract: The present invention is directed to an in vitro method of producing a recombinant AAV virion in a mammalian host cell that comprises a functional adenoviral E1A gene and rAAV virions made by the method. Host cells are transfected with varying ratios of plasmids comprising the E1A gene and virions.
    Type: Grant
    Filed: August 28, 2014
    Date of Patent: August 3, 2021
    Assignee: Amgen Inc.
    Inventors: Huiren Zhao, Grace Ki Jeong Lee, Thomas Wolfe, Cherylene Plewa, Jackie Z. Sheng
  • Means and methods for treating HSV
    Patent number: 11058765
    Abstract: The present invention relates to a vaccine composition comprising a multimeric complex of Herpes Simplex Virus (HSV) polypeptides for the treatment or vaccination against HSV. The present invention also relates to a vector comprising a polynucleotide encoding the HSV polypeptides and a host cell comprising the vector. The present invention further comprises a method for producing the vaccine composition.
    Type: Grant
    Filed: March 14, 2017
    Date of Patent: July 13, 2021
    Assignee: REDBIOTEC AG
    Inventors: Garyfalia Stergiou, Christian Schaub, Corinne John
  • Mutated rep encoding sequences for use in AAV production
    Patent number: 11060070
    Abstract: Nucleic acids encoding Parvoviral Rep proteins with a mutated nuclear localization signal (NLS) are provided. Also provided is a nucleic acid comprising a nucleotide sequence encoding a Parvoviral Rep protein with a mutated zinc finger domain and a nucleic acid comprising a nucleotide sequence encoding a Parvoviral Rep protein comprising an amino acid mutation at position 43, 57, 79, 97, 120, 179, 305, 484, 493 or 571 with reference to SEQ ID NO: 2. Nucleic acid constructs and cells, such as insect cells, comprising the nucleic acids are provided as well as a method for producing a recombinant Parvoviral virion using the nucleic acids.
    Type: Grant
    Filed: July 17, 2019
    Date of Patent: July 13, 2021
    Assignee: UNIQURE IP B.V.
    Inventors: Yvet Noordman, Jacek Lubelski, Andrew Christian Bakker
  • Varicella zoster virus (VZV) vaccine
    Patent number: 11045540
    Abstract: Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include at least one RNA polynucleotides having an open reading frame encoding at least one varicella zoster virus (VZV) antigen. Methods for preparing and using such vaccines are also described.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: June 29, 2021
    Assignee: ModernaTX, Inc.
    Inventor: Giuseppe Ciaramella
  • Affenadenovirus (gorilla) or adenoviral vectors and methods of use
    Patent number: 11034975
    Abstract: The invention provides an adenovirus or adenoviral vector characterized by comprising one or more particular nucleic acid sequences or one or more particular amino acid sequences, or portions thereof, pertaining to, for example, an adenoviral pIX protein, DNA polymerase protein, penton protein, hexone protein, and/or fiber protein.
    Type: Grant
    Filed: February 22, 2019
    Date of Patent: June 15, 2021
    Assignee: GenVec, Inc.
    Inventors: Jason G. D. Gall, Duncan McVey, Douglas E. Brough
  • Recombinant viral vector systems expressing exogenous feline paramyxovirus genes and vaccines made therefrom
    Patent number: 11033616
    Abstract: The present invention relates to exogenous feline paramyxovirus genes, which are expressed from recombinant viral vector systems.
    Type: Grant
    Filed: February 20, 2019
    Date of Patent: June 15, 2021
    Inventors: Hervé Poulet, Veljko Nikolin, Abraham Johannes De Smit, Teshome Mebatsion
  • Scalable purification method for AAVRH10
    Patent number: 11028372
    Abstract: A two-step chromatography purification scheme is described which selectively captures and isolates the genome-containing rAAV vector particles from the clarified, concentrated supernatant of a rAAV production cell culture. The process utilizes an affinity capture method performed at a high salt concentration followed by an anion exchange resin method performed at high pH to provide rAAV vector particles which are substantially free of rAAV intermediates.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: June 8, 2021
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Martin Lock, Mauricio Alvira
  • Porcine epidemic diarrhea preventative or therapeutic method, vaccine, and vaccine kit
    Patent number: 11013797
    Abstract: A method for preventing or treating porcine epidemic diarrhea, the method including: administering a live vaccine of a porcine epidemic diarrhea virus and an adjuvant to a pig through oral administration or nasal administration; and administering an inactivated vaccine of the porcine epidemic diarrhea virus and an adjuvant to the pig through intramuscular administration.
    Type: Grant
    Filed: July 24, 2017
    Date of Patent: May 25, 2021
    Assignees: NIPPON INSTITUTE FOR BIOLOGICAL SCIENCE, NISSEIKEN CO., LTD.
    Inventors: Tetsuo Sato, Kazuki Oroku, Yoshiyuki Ohshima, Yoshiaki Furuya, Nobuyuki Tsutsumi
  • Scalable purification method for AAV1
    Patent number: 11015173
    Abstract: A two-step chromatography purification scheme is described which selectively captures and isolates the genome-containing rAAV vector particles from the clarified, concentrated supernatant of a rAAV production cell culture. The process utilizes an affinity capture method performed at a high salt concentration followed by an anion exchange resin method performed at high pH to provide rAAV vector particles which are substantially free of rAAV intermediates.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: May 25, 2021
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Martin Lock, Mauricio Alvira
  • Scalable purification method for AAV8
    Patent number: 11015174
    Abstract: A two-step chromatography purification scheme is described which selectively captures and isolates the genome-containing rAAV vector particles from the clarified, concentrated supernatant of a rAAV production cell culture. The process utilizes an affinity capture method performed at a high salt concentration followed by an anion exchange resin method performed at high pH to provide rAAV vector particles which are substantially free of rAAV intermediates.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: May 25, 2021
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Martin Lock, Mauricio Alvira
  • Vaccines having an antigen and interleukin-21 as an adjuvant
    Patent number: 11007265
    Abstract: Disclosed herein is a vaccine comprising an antigen and IL-21. Also disclosed herein are methods for increasing an immune response in a subject. The methods may comprise administering the vaccine to the subject in need thereof.
    Type: Grant
    Filed: November 6, 2018
    Date of Patent: May 18, 2021
    Assignees: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, INOVIO PHARMACEUTICALS, INC.
    Inventors: David B. Weiner, Matthew P. Morrow
  • Human cytomegalovirus comprising exogenous antigens
    Patent number: 10995121
    Abstract: Human cytomegalovirus vectors comprising heterologous antigens are disclosed. The vectors derived from the TR strain, are ganciclovir-sensitive, include active US2, US3, US6, US7 and UL131A genes, and have a deleterious or inactivating mutation in the UL82 gene preventing the expression of pp71.
    Type: Grant
    Filed: August 20, 2019
    Date of Patent: May 4, 2021
    Assignee: Oregon Health & Science University
    Inventors: Klaus Frueh, Scott G. Hansen, Jay Nelson, Louis Picker, Patrizia Caposio
  • Recombinant herpes simplex virus 2 (HSV-2) vaccine vectors
    Patent number: 10980874
    Abstract: Recombinant herpes simplex virus 2 (HSV-2) vaccine vectors, virions thereof, compositions and vaccines comprising such, and methods of use thereof are each provided.
    Type: Grant
    Filed: August 18, 2020
    Date of Patent: April 20, 2021
    Assignee: ALBERT EINSTEIN COLLEGE OF MEDICINE
    Inventors: William Jacobs, Jr., Pablo A. Gonzalez-Munoz, Betsy Herold, Christopher Petro
  • Methods of making fucosylated and afucosylated forms of a protein
    Patent number: 10975168
    Abstract: The present application relates to methods of producing a protein in fucosylated and afucosylated forms at a predetermined ratio.
    Type: Grant
    Filed: May 1, 2018
    Date of Patent: April 13, 2021
    Assignee: GENENTECH, INC.
    Inventors: Shahram Misaghi, John B. Lowe, Bradley Richard Snedecor